Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 December;60(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 December;60(4):354-61

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  AN UPDATE ON NUCLEAR CARDIOLOGYFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 December;60(4):354-61

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy

Roberto SCIAGRÀ

Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy


FULL TEXT  


In the setting of hypertrophic cardiomyopathy (HCM), ischemia plays a possibly under-evaluated role. In particular, a large body of evidence indicates that structural and functional abnormalities in the coronary microcirculation contribute to myocardial ischemia and are key elements for HCM pathophysiology and clinical evolution. Measurement of myocardial blood flow (MBF) at rest and under maximal hyperemia (hMBF) by means of perfusion positron-emission tomography (PET) is the most effective way to assess microvascular dysfunction in humans. Therefore, hMBF abnormalities reflect HCM severity and correlate with other important features, such as ischemic symptoms and myocardial fibrosis. Most importantly, it has been demonstrated that severely blunted hMBF implies an adverse outcome in HCM patients. Therefore, PET could be helpful for stratifying patient prognosis and should be used in selected patient subsets to identify those at risk of unfavorable evolution.

inizio pagina

Publication History

Per citare questo articolo

Sciagrà R. Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy. Q J Nucl Med Mol Imaging 2016 December;60(4):354-61. 

Corresponding author e-mail

roberto.sciagra@unifi.it